Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

This study has been completed.

Sponsor:

Information provided by:

Shanghai Jiao Tong University School of Medicine

ClinicalTrials.gov Identifier:

NCT00561704

First received: November 20, 2007

Last updated: NA

Last verified: November 2007

History: No changes posted

Purpose

Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

Condition	Intervention
Obese Type 2 Diabetes Diabetic Nephropathy Glucose Metabolism Angiotensin II Type 1 Receptor Blockers	Drug: losartan


Study Type:	Interventional
Study Design:	Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Type 2 Diabetic Kidney Problems Kidney Diseases

Drug Information available for: Losartan Losartan potassium

U.S. FDA Resources

Further study details as provided by Shanghai Jiao Tong University School of Medicine:

Primary Outcome Measures:

GFR, HbA1c and the adiponectin concentration. [ Time Frame: 6 month ]


Enrollment:	80
Study Start Date:	April 2007
Study Completion Date:	October 2007

Intervention Details:

losartan, 100mg daily,

Detailed Description:

it would be a prospective cohort study. According to BMI, all the women, aged>30yr, diagnosed type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index( fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg daily, 6 month). during the study, the above mentioned parameters will also be recorded 3 month intervals. Meanwhile, any side effects would be pay attention.

Eligibility


Ages Eligible for Study:	30 Years and older (Adult, Senior)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 2 diabetic nephropathy
CKD at stage 1~4

Exclusion Criteria:

Type 1 diabetes or nondiabetic renal disease
An elevated plasma K level.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00561704

Sponsors and Collaborators

Shanghai Jiao Tong University School of Medicine

Investigators


Principal Investigator:	hui min Jin, MD	shanghai No 3 people's hospital

More Information


ClinicalTrials.gov Identifier:	NCT00561704 History of Changes
Other Study ID Numbers:	ADL
Study First Received:	November 20, 2007
Last Updated:	November 20, 2007
Health Authority:	China: Food and Drug Administration

Keywords provided by Shanghai Jiao Tong University School of Medicine:


obese female Type 2 Diabetes Diabetic Nephropathy	Glucose Metabolism Angiotensin II Type 1 Receptor Blockers Adiponectin

Additional relevant MeSH terms:


Diabetes Mellitus, Type 2 Kidney Diseases Diabetic Nephropathies Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Urologic Diseases	Diabetes Complications Losartan Angiotensin II Type 1 Receptor Blockers Anti-Arrhythmia Agents Antihypertensive Agents Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 27, 2016

To Top